Navigation Links
Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
Date:6/9/2008

and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza is available online at http://www.alexza.com.

Safe Harbor Statement

This press release includes forward-looking statements regarding the potential timing of the announcement of results of the AZ-004 Phase 3 clinical trial, potential benefits of AZ-004, future development of the Company's product candidates and safety of the Company's products and technologies. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission including the risks under the headings: "Failure or delay in commencing or completing clinical trials for our product candidates could harm our business" and "If our product candidates do not meet safety and efficacy endpoints in clinical trials, they will not receive regulatory approval, and we will
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, Inc. ... announced it has completed the sale to Galderma of ... owned or held by Valeant for $1.4 billion in ... S.A, which recently completed its acquisition of Galderma. ... of our products to a company that is firmly ...
(Date:7/10/2014)... CVS Caremark Corporation (NYSE: CVS ) ... quarterly dividend of $0.275 (27.5 cents) per share on the ... 2014, to holders of record on July 21, 2014. ... dedicated to helping people on their path to better health ... United States . Through the company,s more than 7,600 ...
(Date:1/15/2014)... Most osteoporosis patients want a choice in the ... sponsored by Mission Pharmacal Company. The survey, conducted by ... support community, revealed that 74 percent of osteoporosis patients ... form other than a pill or a tablet. ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
... used an electronic clinical system since its inception in 2009 ... technology with an enterprise clinical and financial solution from Prognosis ... out as a completely electronic hospital. But we realize that ... of our needs," says Jeremy Lyman, CFO at the 11-bed, ...
... IOD Incorporated™, a leading provider of integrated HIM ... announced its response to the Health and Human Services ... from October 1, 2013 to October 1, 2014. ... to HHS regulations published in 2009, the current ICD-9 ...
Cached Medicine Technology:Blue Mountain Hospital Selects Enterprise System from Prognosis HIS 2Blue Mountain Hospital Selects Enterprise System from Prognosis HIS 3IOD Incorporated Advises Healthcare Providers to Stay the Course in Preparation for ICD-10 2IOD Incorporated Advises Healthcare Providers to Stay the Course in Preparation for ICD-10 3
(Date:7/13/2014)... July 13, 2014 ECS ... commented, “As a parent of a special needs child, ... in the Seattle community for contemporary special education resources ... important alternative to students and families in the Seattle ... and environment for special education. We welcome the opportunity ...
(Date:7/13/2014)... If Dr. Lawrence Power has his way, ... at http://www.HealthYourself101.com will expand people’s understanding of the ... has set out to provide a health education platform on ... dare we say it? – entertaining to dig into and ... engage the remote learner – the solitary individual signing on ...
(Date:7/13/2014)... 13, 2014 According to the Living ... is a comprehensive guide that features a series of ... KP (keratosis pilaris). This guide consists of 14 ... Keratosis Pilaris? ,     Chapter 2: What Cause KP? ... I Have KP? ,     Chapter 4: Keratosis Pilaris ...
(Date:7/12/2014)... According to the new market research report "Security and ... Systems) - Global Forecasts and Analysis to 2014 - ... are estimated to be $6.08 billion in 2014 and ... reach $8.61 billion by 2020. , Browse more than ... 161 pages and in-depth TOC on "Security and Surveillance ...
(Date:7/12/2014)... one of the world’s leading wedding dress suppliers, has announced ... more, all these hot outfits are available at discounted prices, ... “We are proud to announce our new red evening dresses. ... In addition to the big discounts, low shipping costs also ... mean bad quality. All the red evening gowns are made ...
Breaking Medicine News(10 mins):Health News:New Private School, Emerald City School, Founded in Downtown Seattle Now Accepting 1st to 6th Grade Students Who Learn Differently 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 3Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 4Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 3Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Discounted Red Evening Gown Announced by iFitDress.com 2
... atrophy of their temporal lobe or damage to blood ... Alzheimers disease . ,Older adults showing signs ... Alzheimers than their peers. ,Alzheimers disease, a highly ... with other risk factors such as poor cognitive scores, ...
... the University of Southern California have identified a chemical ... brain to low blood sugar levels . ... to yield new insights in the fight against diabetes, ... the researchers, the chemical travels from the hindbrain, which ...
... Australian actress Toni Collette is expecting her first child with ... the news, and said that she and her hubby are ... happy. We are completely over the moon," News.com.au quoted the ... playing pregnant women in many of her films of late, ...
... ,Pull on rubber gloves. ,Smear Vaseline over your glasses , ,and there you have ... ... - Malcolm Cowley ,Hormone ... estrogen and often progesterone for post-menopausal women. ,The two ...
... Internet for conditions ranging from cold sores and shingles ... to prevent aging, enhance fertility, prevent cancer and get ... cadmium. , ,Selenium supplements have shown some ... activities, some scientists feel it might be effective against ...
... actor would never have slept with Marilyn Monroe, for she was ... that the two had a torrid sex romp on the set ... heart attack. ,However, author David Bret in his biography ... rumour was just not true. ,Bret writes that the ...
Cached Medicine News:Health News:Neurotransmitter That can Yield New Insights in the Fight Against Diabetes Identified 2Health News:Hormone Replacement Therapy Liberation at a Cost 2Health News:Hormone Replacement Therapy Liberation at a Cost 3Health News:Selenium Supplements Could Increase Diabetes Risk 2Health News:Selenium Supplements Could Increase Diabetes Risk 3
The TransNeb is a complete medication delivery system in a bag. The TransNeb is a compact, piston compressor providing high-performance while weighing only 11 oz. Versatility. Dependability. Simplici...
... A lightweight (4.2lbs) portable unit with a unique ... It features an oil free aluminum alloy integrated ... Available in a variety of combinations with ... Carrying bag is also available. , ...
The ACMI TurboFlow 18 L and 10 L Insufflators provide rapid distention for all laparoscopic procedures. Eleven built-in safety features make insufflation reliable and dependable....
... GenoID's kit is the first ... HPV for clinical diagnostic use. , ... high-risk and 5 low-risk genotypes of ... of PCR technology but simplifying the ...
Medicine Products: